Urolithiasis in HIV-positive patients treated with atazanavir.
Among protease inhibitors, atazanavir has not been associated with urolithiasis in clinical studies. We describe 11 cases of atazanavir-associated urolithiasis in patients with human immunodeficiency virus (HIV) infection. Patients with low water intake, high urinary pH, and a prior history of urinary stones may have a higher risk of atazanavir-associated urine crystallization.
Couzigou
Carine
C
Service des Maladies Infectieuses et Tropicales, AP-HP, Hôpital Paul Brousse, Villejuif, France. couzigou@yahoo.fr
Daudon
Michel
M
Meynard
Jean Luc
JL
Borsa-Lebas
Françoise
F
Higueret
Denise
D
Escaut
Lélia
L
Zucman
David
D
Liotier
Jean-Yves
JY
Quencez
Jean-Louis
JL
Asselah
Karine
K
May
Thierry
T
Neau
Didier
D
Vittecoq
Daniel
D
D000328:Adult; D000069446:Atazanavir Sulfate; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects* / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D014556:Urine / Q000737:chemistry; D052878:Urolithiasis / Q000139:chemically induced*; D014867:Water / Q000378:metabolism
D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D014867:Water; D000069446:Atazanavir Sulfate